The changing landscape in metastatic castration-resistant prostate cancer

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 3, 2013, Pages 243-248

  Leibowitz Amit, Raya ^a   Joshua, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Abiraterone; Cabozanitinb; Docetaxel; Enzalutamide; Prostate cancer; Radium 223

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CABAZITAXEL; CABOZANTINIB; DRUG DERIVATIVE; ENZALUTAMIDE; PHENYLTHIOHYDANTOIN; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; RADIOISOTOPE; RADIUM; RADIUM CHLORIDE RA 223; TAXOID;

CASTRATION RESISTANT PROSTATE CANCER; DRUG ANTAGONISM; HUMAN; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIDINES; QUALITY OF LIFE; RADIOISOTOPES; RADIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES; TAXOIDS;

EID: 84887946718     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328362ffef     Document Type: Review

References (29)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43:209-223.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261.
3. Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012; 19 (Suppl. 3):S22-S31.
4. Bryce A, Ryan CJ. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther 2012; 91:101-108.
5. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-992.
6. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
7. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148.
8. Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castrationresistant prostate cancer (mCRPC): Updated data from a phase I/II study. ASCO Meeting Abstracts 2011; 29 (15-Suppl.):4531.
9. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197.
11. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494-1503.
12. Smith MR, Antonarakis ES, Ryan CJ, et al. ARN-509 in men with highrisk nonmetastatic castration-resistant prostate cancer (CRPC). ASCO GU Symposium 2013. General Poster Session A (#A7).
13. Rathkopf DE, Antonarakis ES, Shore ND, et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO GU Symposium 2013. General Poster Session A (#D3).
14. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
15. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
16. Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care 2012; 6:310-315.
17. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62:3120-3125.
18. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
19. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
20. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47 (Suppl. 2):3.
21. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). ASCO Meeting Abstracts 2012; 30 (18-Suppl.): LBA4512.
22. Nilsson S, Sartor AO, Bruland OS, et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. ASCO GU Symposium 2013. General Poster Session A (#B10).
23. Pisters LL, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995; 154:293-298.
24. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31:412-419.
25. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29:4022-4028.
26. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
27. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822.
28. Pezaro CJ, Le Moulec S, Albiges L, et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. ASCO Meeting Abstracts 2013; 31 (6 Suppl.):155.
29. Reuter CW, Morgan MA, Fenner M, et al. Effectiveness of abiraterone as salvage therapy in patients with docetaxel-and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC). ASCO Meeting Abstracts 2013; 31 (6-Suppl.):162.